IMR Press / EJGO / Volume 39 / Issue 6 / DOI: 10.12892/ejgo4669.2018

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Distinguished Expert Series
Surgical staging and differential protein expression in endometrial cancers
Show Less
1 Kaiser Permanente Washington, Bellevue, WA, USA
Eur. J. Gynaecol. Oncol. 2018, 39(6), 859–866; https://doi.org/10.12892/ejgo4669.2018
Published: 10 December 2018
Abstract

Purpose of Investigation: The benefit of comprehensive surgical staging in type I versus type II tumors is investigated and translationally associated with differentially expressed proteins. Materials and Methods: A single institutional database was queried for all uterine cancer patients and sample data was abstracted. Proteins identified from microarray data were further investigated at the immunohistochemical (IHC) level and correlated with sample data. Results: Lymph node dissection did not result in a survival benefit for either type I or type II uterine cancer. L1CAM is differentially expressed between tumor types. GRB7 was found to correlate with stage in type II cancers. Thrombomodulin was expressed at higher levels in all lymph node (LN) positive cancers. Conclusions: LN dissection did not provide a therapeutic benefit in endometrial cancers, especially type II cancers. Protein correlations with stage and histology demonstrate specific biologic profiles. Novel diagnostic and therapeutic targets for differentially expressed tumor proteins are identified.
Keywords
Immunohistochemistry
Lymph node
Uterine cancer
Share
Back to top